Spots Global Cancer Trial Database for Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer
Official Title: Phase II Trial of FOLFOXIRI + Bevacizumab in Patients With Untreated Metastatic Colorectal Cancer
Study ID: NCT02497157
Conditions
Study Description
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of fluorouracil (5-FU), levofolinate calcium (l-LV), oxaliplatin (L-OHP) and irinotecan hydrochloride hydrate (CPT-11) (FOLFOXIRI) plus bevacizumab in untreated metastatic colorectal cancer patients who harbor Uridine diphosphate (UDP)-glucuronosyl transferase 1A1 (UGT1A1) \*1/\*1, \*1/\*6 or \*1/\*28.
Detailed Description:
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Matsuyama Red Cross Hospital, Matsuyama-city, Ehime-prefecture, Japan
Kagawa University Hospital, Kita-gun, Miki-cho, Kagawa-prefecture, Japan
Kawasaki Medical School Hospital, Kurashiki-city, Okayama-prefecture, Japan
Okayama Saiseikai General Hospital, Okayama-city, Okayama-prefecture, Japan
Okayama University Hospital, Okayama-city, Okayama-prefecture, Japan
Okayama Rosai Hospital, Okayama-city, Okayama-prefecture, Japan
Tokushima Red Cross Hospital, Komatsushima-city, Tokushima-prefecture, Japan
Contact Details
Name: Katsunori Shinozaki, MD, Ph.D.
Affiliation: Hiroshima Prefectural Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Tomohiro Nishina, MD, Ph.D.
Affiliation: National Hospital Organization Shikoku Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
